Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$14.05 USD

14.05
4,310,210

-0.26 (-1.82%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $14.04 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel (QDEL) is likely to have witnessed recovery in rapid immunoassay revenues during Q1.

Urmimala Biswas headshot

4 Medical Products Stocks Set to Beat This Earnings Season

by Urmimala Biswas

Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.

Zacks Equity Research

Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in Pharmaceutical segment.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect weak segmental performance.

Zacks Equity Research

BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?

by Zacks Equity Research

BD's (BDX) second-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.

Zacks Equity Research

Cerner (CERN) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Cerner's (CERN) first-quarter results are likely to reflect gains from strategic deals.

Zacks Equity Research

Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q1.

Zacks Equity Research

DaVita (DVA) Q1 Earnings Beat Estimates, Revenues Miss Mark

by Zacks Equity Research

DaVita's (DVA) net dialysis and related lab-patient service revenues rise in Q1.

Zacks Equity Research

XRAY vs. ALGN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

XRAY vs. ALGN: Which Stock Is the Better Value Option?

Zacks Equity Research

McKesson (MCK) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

Zacks Equity Research

Omnicell (OMCL) Q1 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Omnicell's (OMCL) raises adjusted EPS guidance for 2021 , which buoys optimism.

Zacks Equity Research

AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

Zacks Equity Research

DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth.

Zacks Equity Research

Teleflex (TFX) Beats on Q1 Earnings and Revenues, Raises View

by Zacks Equity Research

The acquisition of Z-Medica and an increase in sales of new products contribute to Teleflex's (TFX) revenue growth in Americas in Q1

Zacks Equity Research

Dentsply International (XRAY) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.

Zacks Equity Research

Surmodics (SRDX) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Surmodics (SRDX) records higher revenues in both its core units in the fiscal second quarter.

Zacks Equity Research

CONMED (CNMD) Earnings and Revenue Surpass Estimates in Q1

by Zacks Equity Research

CONMED (CNMD) witnesses growth in revenues in both its segments during Q1.

Zacks Equity Research

LabCorp (LH) Q1 Earnings Surpass Estimates, View Raised

by Zacks Equity Research

LabCorp's (LH) raises 2021 guidance but projects significant sinking of COVID-related testing revenues.

Zacks Equity Research

Amedisys (AMED) Q1 Earnings Beat Estimates, 2021 View Up

by Zacks Equity Research

Amedisys' (AMED) first-quarter 2021 revenues improves year over year on solid growth in the Home Health and Hospice divisions.

Zacks Equity Research

OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top

by Zacks Equity Research

OPKO Health's (OPK) first-quarter results benefit from strength in diagnostics.

Zacks Equity Research

Integra (IART) Q1 Earnings Beat Estimates, Gross Margin Down

by Zacks Equity Research

Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.

Zacks Equity Research

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) first-quarter results reflect robust performance across five of its business units.

Zacks Equity Research

Chemed (CHE) Q1 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Chemed's (CHE) first-quarter 2021 revenues increase year-over-year on solid growth across its Roto-Rooter arm.

Zacks Equity Research

Accuray (ARAY) Posts Breakeven Q3 Earnings, Beats on Revenues

by Zacks Equity Research

Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q3.